<?xml version="1.0" encoding="UTF-8"?>
<list list-type="bullet" id="list8-0020731420946590">
 <list-item>
  <p>“Increased access to highly effective direct-acting antivirals (DAAs) for the treatment of infection with the hepatitis C virus (HCV) is revolutionizing the prospect of ending HCV epidemics,” the World Health Organization (WHO) stated in March 2018. However, there is no vaccine.
   <sup>44,45</sup>
  </p>
 </list-item>
 <list-item>
  <p>Transmission is primarily transmitted during injections, in health care settings, and during transfusion of unscreened blood, but some sexual transmission occurs and it can be passed from infected mothers to infants. HCV becomes chronic in 50% of cases.
   <sup>46</sup>
  </p>
 </list-item>
 <list-item>
  <p>71 million people have been infected with HCV. Chronic hepatitis results in at least 75% of patients.</p>
 </list-item>
 <list-item>
  <p>Today, CFR is low. From 2003 to 2013, CFR ranged from 0.3% over 5.7 years to 9.2% over 8.2 years of follow-up in community samples. Among treated patients achieving sustained viral response, liver-specific case fatality was low: up to 1.4% over 11.5 years of follow-up.
   <sup>
    <xref rid="bibr47-0020731420946590" ref-type="bibr">47</xref>
   </sup> In the United States, the mortality rate began to decline in 2014.
   <sup>
    <xref rid="bibr48-0020731420946590" ref-type="bibr">48</xref>
   </sup> New treatments can cure more than 95%.
  </p>
 </list-item>
 <list-item>
  <p>Each year, 399,000 die. This number is likely to be largely underestimated.</p>
 </list-item>
 <list-item>
  <p>Health care workers are especially at risk, due to needle sticks involving HCV-positive blood.</p>
 </list-item>
 <list-item>
  <p>In Europe, 14 million are chronically infected, and 112,500 die per year from HCV-related cancer and cirrhosis.</p>
 </list-item>
</list>
